Catalyst Event

Amgen Inc (AMGN) · Other

From Akros U.S. Large Cap 500 Protective Allocation Monthly Index (A500PAM)

6/7/2026, 12:00:00 AM

OtherSentiment: Positive

Presented new Phase 3 VESALIUS-CV trial data for Repatha at the ADA Scientific Sessions on June 7, 2026; significant clinical success in high-risk patients is estimated to drive a 5-10% price impact, scheduled.

Korean Translation

2026년 6월 7일 ADA 과학 세션에서 레파타(Repatha)의 3상 임상 데이터 발표로 인한 5-10%의 주가 영향이 예상되며, 해당 일정은 예정됨.

Related Recent Events

View Full Timeline